AB
Therapeutic Areas
CG Oncology Pipeline
| Drug | Indication | Phase |
|---|---|---|
| Cretostimogene grenadenorepvec (CG0070) | BCG-unresponsive NMIBC with Carcinoma in Situ (CIS) ± Ta/T1 tumors | Phase 3 |
| Cretostimogene grenadenorepvec | BCG-naïve High-Risk NMIBC | Phase 3 |
| Cretostimogene + Pembrolizumab | BCG-unresponsive NMIBC (CIS-containing) | Phase 2 |
| Cretostimogene + Nivolumab | Muscle-Invasive Bladder Cancer (MIBC) | Phase 2 |
Leadership Team at CG Oncology
AK
Arthur Kuan
Chairman & Chief Executive Officer
VK
Vijay Kasturi
Chief Medical Officer
SB
Swapnil Bhargava
Chief Technical Officer
JP
Josh Patterson
General Counsel & Chief Compliance Officer
SE
Susan E. Graf
Board Member
BL
Brian Liu
Board Member
JM
Jim Mulé
Board Member
LP
Leonard Post
Board Member
CR
Christina Rossi
Board Member
VT
Victor Tong, Jr.
Board Member